Ataraxis AI

Ataraxis AI is a clinical-stage AI company spun out of New York University in 2023, focused on developing and deploying AI-powered tools to improve cancer prognosis and treatment selection. The company has raised a $20.4 million Series A round and has launched its first product, Ataraxis Breast, a prognostic tool that delivers results within 24 hours using existing pathology slides. Backed by a world-class team and advisors like AI pioneer Yann LeCun, Ataraxis is collaborating with top international cancer centers to validate and implement its technology across multiple cancer types.

Proprietary AI platform using multi-modal learning and self-supervised foundation models (e.g., Kestrel) trained on hundreds of millions of pathology images to extract novel morphological biomarkers for cancer prognosis and treatment response prediction.

Ataraxis competes with established genomic test providers (e.g., Exact Sciences' Oncotype DX) on speed and tissue conservation, and with AI-pathology companies (e.g., PathAI, Paige) by focusing on standalone prognostic tests rather than pathologist workflow tools. Its differentiation lies in its clinically deployed product, proprietary pan-cancer foundation model, and strong academic-AI research foundation.